Viking Therapeutics Inc (NASDAQ: VKTX) started the day on Thursday, with a price decrease of -2.04% at $31.63, before settling in for the price of $32.29 at the close. Taking a more long-term approach, VKTX posted a 52-week range of $28.64-$99.41.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 0.00%. Meanwhile, its Annual Earning per share during the time was -23.00%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -57.98%. This publicly-traded company’s shares outstanding now amounts to $111.57 million, simultaneously with a float of $108.10 million. The organization now has a market capitalization sitting at $3.52 billion. At the time of writing, stock’s 50-day Moving Average stood at $37.73, while the 200-day Moving Average is $54.72.
Viking Therapeutics Inc (VKTX) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Viking Therapeutics Inc’s current insider ownership accounts for 3.00%, in contrast to 74.25% institutional ownership. According to the most recent insider trade that took place on Jan 06 ’25, this organization’s President & CEO sold 194,490 shares at the rate of 42.75, making the entire transaction reach 8,313,601 in total value, affecting insider ownership by 2,366,570. Preceding that transaction, on Jan 06 ’25, Company’s Chief Operating Officer sold 54,215 for 42.75, making the whole transaction’s value amount to 2,317,599. This particular insider is now the holder of 374,134 in total.
Viking Therapeutics Inc (VKTX) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.36 per share during the current fiscal year.
Viking Therapeutics Inc’s EPS decrease for this current 12-month fiscal period is -57.98% and is forecasted to reach -2.16 in the upcoming year.
Viking Therapeutics Inc (NASDAQ: VKTX) Trading Performance Indicators
Let’s observe the current performance indicators for Viking Therapeutics Inc (VKTX). It’s Quick Ratio in the last reported quarter now stands at 36.47. The Stock has managed to achieve an average true range (ATR) of 2.27.
In the same vein, VKTX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.01, a figure that is expected to reach -0.33 in the next quarter, and analysts are predicting that it will be -2.16 at the market close of one year from today.
Technical Analysis of Viking Therapeutics Inc (VKTX)
If we take a close look at the recent performances of Viking Therapeutics Inc (NASDAQ: VKTX), its last 5-days Average volume was 4.56 million that shows progress from its year to date volume of 4.13 million. During the previous 9 days, stock’s Stochastic %D was recorded 42.56% While, its Average True Range was 2.26.
Raw Stochastic average of Viking Therapeutics Inc (VKTX) in the period of the previous 100 days is set at 5.63%, which indicates a major fall in contrast to 48.70% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 71.23% that was lower than 75.75% volatility it exhibited in the past 100-days period.
